TRIAL COMPARING 5-FU PLUS LEUCOVORIN AND OXALIPLATIN IN CARCINOMA OF THE COLON

比较 5-FU 加亚叶酸和奥沙利铂治疗结肠癌的试验

• 批准号: 7376243
• 负责人: EUGENE A WOLTERING
• 金额: $ 0.29万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376243
• 关键词: TRIAL; COMPARING; FU; PLUS; LEUCOVORIN

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Colorectal cancer is the third most common cause of death from malignancy in both males and females in the U.S. Although surgery remains the mainstay of treatment for stage II and III colorectal cancer, it is curative only in some patients. Studies from the NSABP and other cooperative groups have clearly demonstrated that adjuvant chemotherapy has altered the natural history for patients with stage II and III colorectal cancer. Two approaches have resulted in improvement in disease-free survival (DFS) and survival (S). Despite adjuvant chemotherapy, about one-third of patients with colorectal cancer will develop a recurrence within five years of surgery. Thus, there continues to be a need to evaluate new treatments for this disease. New treatment strategies and more effective drugs or combinations of drugs are needed to further improve outcome in these individuals. The hypothesis for this trial is that an effective first-line advanced colorectal cancer treatment may improve disease-free survival and overall survival in the adjuvant setting. Oxaliplatin has demonstrated clinical synergism with 5-FU + LV in randomized clinical trials. It is appropriate to evaluate the efficacy of the combination in an adjuvant setting.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。结直肠癌是美国男性和女性恶性肿瘤死亡的第三大常见原因。虽然手术仍然是II期和III期结直肠癌治疗的主要手段，但仅对某些患者有效。NSABP和其他合作小组的研究清楚地表明，辅助化疗改变了II期和III期结直肠癌患者的自然病程。两种方法导致无病生存期（DFS）和生存期（S）的改善。 尽管有辅助化疗，约三分之一的结直肠癌患者将在手术后五年内复发。因此，仍然需要评估这种疾病的新治疗方法。需要新的治疗策略和更有效的药物或药物组合来进一步改善这些个体的结果。 这项试验的假设是，有效的一线晚期结直肠癌治疗可能会提高辅助治疗的无病生存率和总生存率。在随机临床试验中，奥沙利铂已证明与5-FU + LV具有临床协同作用。在辅助治疗情况下评价联合用药的疗效是适当的。